

## HR 4207

### Medicare Fair Drug Pricing Act of 2015

**Congress:** 114 (2015–2017, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Dec 9, 2015

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Dec 11, 2015)

**Official Text:** <https://www.congress.gov/bill/114th-congress/house-bill/4207>

## Sponsor

**Name:** Rep. Schakowsky, Janice D. [D-IL-9]

**Party:** Democratic • **State:** IL • **Chamber:** House

## Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Dec 9, 2015
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Dec 9, 2015
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Dec 9, 2015
Rep. Lee, Barbara [D-CA-13]	D · CA		Dec 9, 2015
Rep. McDermott, Jim [D-WA-7]	D · WA		Dec 9, 2015
Rep. Pocan, Mark [D-WI-2]	D · WI		Dec 9, 2015
Rep. Welch, Peter [D-VT-At Large]	D · VT		Dec 9, 2015
Rep. Honda, Michael M. [D-CA-17]	D · CA		Feb 2, 2016
Rep. Thompson, Bennie G. [D-MS-2]	D · MS		Feb 2, 2016
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Feb 4, 2016

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 11, 2015
Ways and Means Committee	House	Referred to	Dec 9, 2015

## Subjects & Policy Tags

**Policy Area:**

Health

## Related Bills

No related bills are listed.

## **Medicare Fair Drug Pricing Act of 2015**

This bill amends title XVIII (Medicare) of the Social Security Act to require the Centers for Medicare & Medicaid Services (CMS) to negotiate with drug manufacturers in determining the price that may be charged for prescription drugs under the Medicare prescription drug benefit.

Under current law, CMS may not interfere with negotiations between drug manufacturers and prescription drug plan (PDP) sponsors. The bill creates an exception to this prohibition with respect to specified drugs that: (1) are single-source or biological, (2) are not both manufactured by more than two drug manufacturers and manufactured by at least one manufacturer as a generic drug, and (3) meet other specified requirements. CMS must promulgate regulations regarding the identification of such drugs.

With respect to these drugs, CMS shall negotiate the price that may be charged to PDP sponsors and Medicare Advantage (MA) organizations for Medicare and MA enrollees. The bill establishes processes for negotiation and price determination in the initial plan year and subsequent plan years.

A manufacturer must participate in the negotiation process as a condition of coverage under the Medicare prescription drug benefit.

### **Actions Timeline**

---

- **Dec 11, 2015:** Referred to the Subcommittee on Health.
- **Dec 9, 2015:** Introduced in House
- **Dec 9, 2015:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Dec 9, 2015:** Referred to the Subcommittee on Health.